- Home
- Publications
- Publication Search
- Publication Details
Title
Psoriasis: from Pathogenesis to Targeted Therapies
Authors
Keywords
Psoriasis, Pathogenesis, Inflammatory pathways, Psoriasis comorbidities, Treatments, Biologicals, TNFα inhibitors
Journal
CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY
Volume 54, Issue 1, Pages 102-113
Publisher
Springer Nature
Online
2018-01-18
DOI
10.1007/s12016-018-8668-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The role of the microbiome in psoriasis: moving from disease description to treatment selection?
- (2018) E.A. Langan et al. BRITISH JOURNAL OF DERMATOLOGY
- TNF blockade induces a dysregulated type I interferon response without autoimmunity in paradoxical psoriasis
- (2018) Curdin Conrad et al. Nature Communications
- A safety assessment of biological therapies targeting the IL-23/IL-17 axis in inflammatory bowel diseases
- (2017) Bram Verstockt et al. Expert Opinion On Drug Safety
- IL-1 and IL-36 are dominant cytokines in generalized pustular psoriasis
- (2017) Andrew Johnston et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Cardiovascular event risk assessment in psoriasis patients treated with tumor necrosis factor-α inhibitors versus methotrexate
- (2017) Jashin J. Wu et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Risk of malignancy with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment Registry
- (2017) David Fiorentino et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: A presentation of adjudicated data from an integrated database of 7 randomized controlled and uncontrolled trials
- (2017) Kristian Reich et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: A randomized, double-blind, multicenter, phase III study
- (2017) Kim Papp et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study
- (2017) Andrew Blauvelt et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial
- (2017) Andrew Blauvelt et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24-week, randomized, double-blind, placebo-controlled phase 3b study
- (2017) Jerry Bagel et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Multiple switches between GP2015, an etanercept biosimilar, with originator product do not impact efficacy, safety and immunogenicity in patients with chronic plaque-type psoriasis: 30-week results from the phase 3, confirmatory EGALITY study
- (2017) S. Gerdes et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Apremilast for the treatment of moderate-to-severe palmoplantar psoriasis: results from a double-blind, placebo-controlled, randomized study
- (2017) R. Bissonnette et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials
- (2017) Kristian Reich et al. LANCET
- Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial
- (2017) Kristin K Jørgensen et al. LANCET
- Risk of Tuberculosis Reactivation in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Receiving Non-Anti-TNF-Targeted Biologics
- (2017) Fabrizio Cantini et al. MEDIATORS OF INFLAMMATION
- Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis
- (2017) Kim A. Papp et al. NEW ENGLAND JOURNAL OF MEDICINE
- The association between 38 previously reported polymorphisms and psoriasis in a Polish population: High predicative accuracy of a genetic risk score combining 16 loci
- (2017) Bartłomiej Kisiel et al. PLoS One
- A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis
- (2016) K.A. Papp et al. BRITISH JOURNAL OF DERMATOLOGY
- Safety of secukinumab in the treatment of psoriasis
- (2016) Andrew Blauvelt Expert Opinion On Drug Safety
- Targeting CD8+ T cells prevents psoriasis development
- (2016) Paola Di Meglio et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2)
- (2016) Phoebe Rich et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis
- (2016) Peter C.M. van de Kerkhof et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis
- (2016) Kenneth B. Gordon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up
- (2015) R.G. Langley et al. BRITISH JOURNAL OF DERMATOLOGY
- Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial
- (2015) K. Papp et al. BRITISH JOURNAL OF DERMATOLOGY
- Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials
- (2015) K.A. Papp et al. BRITISH JOURNAL OF DERMATOLOGY
- Melanocyte antigen triggers autoimmunity in human psoriasis
- (2015) Akiko Arakawa et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial
- (2015) Diamant Thaçi et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)
- (2015) Kim Papp et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Improvement of scalp and nail lesions with ixekizumab in a phase 2 trial in patients with chronic plaque psoriasis
- (2015) R.G. Langley et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Development of a Trispecific Antibody Designed to Simultaneously and Efficiently Target Three Different Antigens on Tumor Cells
- (2015) Nazzareno Dimasi et al. MOLECULAR PHARMACEUTICS
- Clinical improvement in psoriasis with specific targeting of interleukin-23
- (2015) Tamara Kopp et al. NATURE
- Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis
- (2015) Mark Lebwohl et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis
- (2015) Kenneth B. Gordon et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Weighted Polygenic Risk Score Using 14 Known Susceptibility Variants to Estimate Risk and Age Onset of Psoriasis in Han Chinese
- (2015) Xianyong Yin et al. PLoS One
- Enhanced meta-analysis and replication studies identify five new psoriasis susceptibility loci
- (2015) Lam C. Tsoi et al. Nature Communications
- Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis
- (2015) Robert E. Kalb et al. JAMA Dermatology
- Immunology of Psoriasis
- (2014) Michelle A. Lowes et al. Annual Review of Immunology
- Partial clinical response to anakinra in severe palmoplantar pustular psoriasis
- (2014) M. Tauber et al. BRITISH JOURNAL OF DERMATOLOGY
- Epidermal Th22 and Tc17 Cells Form a Localized Disease Memory in Clinically Healed Psoriasis
- (2014) S. Cheuk et al. JOURNAL OF IMMUNOLOGY
- Cardiovascular outcomes and systemic anti-inflammatory drugs in patients with severe psoriasis: 5-year follow-up of a Danish nationwide cohort
- (2014) O. Ahlehoff et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials
- (2014) Richard G. Langley et al. NEW ENGLAND JOURNAL OF MEDICINE
- The antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis
- (2014) Roberto Lande et al. Nature Communications
- Successful Treatment of Generalized Pustular Psoriasis With the Interleukin-1-Receptor Antagonist Anakinra: Lack of Correlation With IL1RN Mutations
- (2013) Manuelle Viguier ANNALS OF INTERNAL MEDICINE
- Pharmacogenetics of psoriasis:HLA-Cw6but notLCE3B/3Cdeletion norTNFAIP3polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab
- (2013) M. Talamonti et al. BRITISH JOURNAL OF DERMATOLOGY
- Successful therapy with anakinra in a patient with generalized pustular psoriasis carryingIL36RNmutations
- (2013) U. Hüffmeier et al. BRITISH JOURNAL OF DERMATOLOGY
- Rare Pathogenic Variants in IL36RN Underlie a Spectrum of Psoriasis-Associated Pustular Phenotypes
- (2013) Niovi Setta-Kaffetzi et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Psoriasis Severity and the Prevalence of Major Medical Comorbidity
- (2013) Howa Yeung et al. JAMA Dermatology
- Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease
- (2012) Gerd R Burmester et al. ANNALS OF THE RHEUMATIC DISEASES
- Acitretin- and Tumor Necrosis Factor Inhibitor –Resistant Acrodermatitis Continua of Hallopeau Responsive to the Interleukin 1 Receptor Antagonist Anakinra
- (2012) Virginie Lutz ARCHIVES OF DERMATOLOGY
- Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab′ certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension
- (2012) K. Reich et al. BRITISH JOURNAL OF DERMATOLOGY
- Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial
- (2012) Wolfgang Hueber et al. GUT
- CD8+ T Cells in the Lesional Skin of Atopic Dermatitis and Psoriasis Patients Are an Important Source of IFN-γ, IL-13, IL-17, and IL-22
- (2012) DirkJan Hijnen et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity
- (2012) Lam C Tsoi et al. NATURE GENETICS
- Mutations in IL36RN/IL1F5 Are Associated with the Severe Episodic Inflammatory Skin Disease Known as Generalized Pustular Psoriasis
- (2011) Alexandros Onoufriadis et al. AMERICAN JOURNAL OF HUMAN GENETICS
- Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials
- (2011) K. Reich et al. BRITISH JOURNAL OF DERMATOLOGY
- The ‘psoriatic march’: a concept of how severe psoriasis may drive cardiovascular comorbidity
- (2011) Wolf-Henning Boehncke et al. EXPERIMENTAL DERMATOLOGY
- Association Between Biologic Therapies for Chronic Plaque Psoriasis and Cardiovascular Events
- (2011) Caitriona Ryan et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Interleukin-36–Receptor Antagonist Deficiency and Generalized Pustular Psoriasis
- (2011) Slaheddine Marrakchi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Chronic Mucocutaneous Candidiasis in Humans with Inborn Errors of Interleukin-17 Immunity
- (2011) A. Puel et al. SCIENCE
- Cutting Edge: A Critical Functional Role for IL-23 in Psoriasis
- (2010) G. Tonel et al. JOURNAL OF IMMUNOLOGY
- A randomized, double-blind, placebo-controlled, phase I study of MEDI-545, an anti–interferon-alfa monoclonal antibody, in subjects with chronic psoriasis
- (2010) Robert Bissonnette et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Plasmacytoid dendritic cells in the skin: To sense or not to sense nucleic acids
- (2009) Curdin Conrad et al. SEMINARS IN IMMUNOLOGY
- Interplay between keratinocytes and immune cells—Recent insights into psoriasis pathogenesis
- (2008) Giulia Tonel et al. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
- Impaired TH17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome
- (2008) Joshua D. Milner et al. NATURE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started